LA
ALXN

Lee Ainslie’s Alexion Pharmaceuticals ALXN Stock Holding History

Lee Ainslie’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,420
Closed -$2.1M – 866
2021
Q2 		$2.1M Sell
11,420
-18,889
-62% -$3.24M 0.02% 164
2021
Q1 		$4.63M Buy
+30,309
New +$4.69M 0.04% 78
2020
Q4 		– Sell
-10,959
Closed -$1.25M – 813
2020
Q3 		$1.25M Sell
10,959
-2,475
-18% -$267K 0.02% 220
2020
Q2 		$1.51M Buy
13,434
+11,315
+534% +$1.2M 0.03% 218
2020
Q1 		$190K Buy
+2,119
New +$208K ﹤0.01% 424
2015
Q3 		– Sell
-1,600
Closed -$289K – 133
2015
Q2 		$289K Buy
1,600
+250
+19% +$43.1K ﹤0.01% 58
2015
Q1 		$234K Buy
+1,350
New +$244K ﹤0.01% 118

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Lee Ainslie's ALXN Position: Q3 2021 in Review

Lee Ainslie sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 11,420 shares — an estimated $2.1M sold.

Lee Ainslie first reported a position in ALXN in Q1 2015 and held it in 7 quarters. The position peaked at $4.63M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Lee Ainslie reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Lee Ainslie sold 11,420 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.1M.
  • Lee Ainslie first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 7 quarters.
  • Lee Ainslie's Alexion Pharmaceuticals position peaked at $4.63M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Maverick Capital's 13F filing for Q3 2021, filed 15 Nov 2021.